Notification of delay of decision on denosumab funding proposal
This news item is more than two years old
The information on this page may no longer be accurate. If you have any questions, you can email us at media@pharmac.govt.nz
PHARMAC would like to advise all interested parties that there will be a delay in the decision on a proposal to fund denosumab 60 mg prefilled syringed for the treatment of osteoporosis.
PHARMAC would like to advise all interested parties that there will be a delay in the decision on a proposal to fund denosumab 60 mg prefilled syringed for the treatment of osteoporosis.
The proposal was the subject of a consultation dated 16 March 2018.
Consultation on this proposal closed on 4 April. Some significant issues were raised in consultation responses and we require additional time to consider them before a decision can be made on the proposal.
This delay will mean that a decision will not be made in time to implement the proposed funding changes by 1 June 2018. We do not currently have a firm timeframe for when a decision will be made on this proposal.
If you have any questions about this notification, please contact Alexander Rodgers, Therapeutic Group Manager, by email at alexander.rodgers@pharmac.govt.nz